Zeck has over 20 years experience in drug discovery and development, especially in the therapeutic areas of oncology, CNS, autoimmune diseases (RA, SLE, MS, etc), infectious diseases (COVID-19, HIV, HBV, HVC, etc). He provided regulatory support for Cell and Gene therapeutic products, in addition to small molecules and biologics (such as monoclonal antibodies and other therapeutic proteins). His expertise is nonclinical subjects including pharmacology, ADME/PK, toxicology, and various IND-enabling stuties and requirements for Cell and Gene Therapeutic products.